Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
1991 4
1992 5
1993 9
2005 2
2006 1
2007 4
2008 6
2009 5
2010 1
2011 4
2012 2
2013 2
2014 7
2015 9
2016 6
2017 10
2018 13
2019 13
2020 11
2021 12
2022 10
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma.
Vos JL, Elbers JBW, Krijgsman O, Traets JJH, Qiao X, van der Leun AM, Lubeck Y, Seignette IM, Smit LA, Willems SM, van den Brekel MWM, Dirven R, Baris Karakullukcu M, Karssemakers L, Klop WMC, Lohuis PJFM, Schreuder WH, Smeele LE, van der Velden LA, Bing Tan I, Onderwater S, Jasperse B, Vogel WV, Al-Mamgani A, Keijser A, van der Noort V, Broeks A, Hooijberg E, Peeper DS, Schumacher TN, Blank CU, de Boer JP, Haanen JBAG, Zuur CL. Vos JL, et al. Among authors: de boer jp. Nat Commun. 2021 Dec 22;12(1):7348. doi: 10.1038/s41467-021-26472-9. Nat Commun. 2021. PMID: 34937871 Free PMC article. Clinical Trial.
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn MJ, Soria A, Machiels JP, Mach N, Mehra R, Burtness B, Zhang P, Cheng J, Swaby RF, Harrington KJ; KEYNOTE-040 investigators. Cohen EEW, et al. Lancet. 2019 Jan 12;393(10167):156-167. doi: 10.1016/S0140-6736(18)31999-8. Epub 2018 Nov 30. Lancet. 2019. PMID: 30509740 Clinical Trial.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, Jarzab B, Isaev P, Kopeckova K, Wadsley J, Führer D, Keam B, Bardet S, Sherman EJ, Tahara M, Hu MI, Singh R, Lin Y, Soldatenkova V, Wright J, Lin B, Maeda P, Capdevila J, Wirth LJ; LIBRETTO-531 Trial Investigators. Hadoux J, et al. N Engl J Med. 2023 Nov 16;389(20):1851-1861. doi: 10.1056/NEJMoa2309719. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870969 Clinical Trial.
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.
Armand P, Engert A, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman JM, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Shipp MA, Kato K, Sumbul A, Farsaci B, Ansell SM. Armand P, et al. Among authors: de boer jp. J Clin Oncol. 2018 May 10;36(14):1428-1439. doi: 10.1200/JCO.2017.76.0793. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584546 Free PMC article. Clinical Trial.
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.
Ansell SM, Bröckelmann PJ, von Keudell G, Lee HJ, Santoro A, Zinzani PL, Collins GP, Cohen JB, de Boer JP, Kuruvilla J, Savage KJ, Trněný M, Provencio M, Jäger U, Willenbacher W, Wen R, Akyol A, Mikita-Geoffroy J, Shipp MA, Engert A, Armand P. Ansell SM, et al. Among authors: de boer jp. Blood Adv. 2023 Oct 24;7(20):6266-6274. doi: 10.1182/bloodadvances.2023010334. Blood Adv. 2023. PMID: 37530622 Free PMC article. Clinical Trial.
Predicting transformation in follicular lymphoma.
de Jong D, de Boer JP. de Jong D, et al. Among authors: de boer jp. Leuk Lymphoma. 2009 Sep;50(9):1406-11. doi: 10.1080/10428190903093815. Leuk Lymphoma. 2009. PMID: 19606378 Review.
Long-Term Cause-Specific Mortality in Hodgkin Lymphoma Patients.
de Vries S, Schaapveld M, Janus CPM, Daniëls LA, Petersen EJ, van der Maazen RWM, Zijlstra JM, Beijert M, Nijziel MR, Verschueren KMS, Kremer LCM, van Eggermond AM, Lugtenburg PJ, Krol ADG, Roesink JM, Plattel WJ, van Spronsen DJ, van Imhoff GW, de Boer JP, Aleman BMP, van Leeuwen FE. de Vries S, et al. Among authors: de boer jp. J Natl Cancer Inst. 2021 Jun 1;113(6):760-769. doi: 10.1093/jnci/djaa194. J Natl Cancer Inst. 2021. PMID: 33351090 Free PMC article.
Current treatment options for local residual nasopharyngeal carcinoma.
Stoker SD, van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR, Tan IB. Stoker SD, et al. Among authors: de boer jp. Curr Treat Options Oncol. 2013 Dec;14(4):475-91. doi: 10.1007/s11864-013-0261-5. Curr Treat Options Oncol. 2013. PMID: 24243165 Free PMC article. Review.
EphA2 Targeted Doxorubicin-Nanoliposomes for Osteosarcoma Treatment.
Haghiralsadat F, Amoabediny G, Naderinezhad S, Nazmi K, De Boer JP, Zandieh-Doulabi B, Forouzanfar T, Helder MN. Haghiralsadat F, et al. Among authors: de boer jp. Pharm Res. 2017 Dec;34(12):2891-2900. doi: 10.1007/s11095-017-2272-6. Epub 2017 Nov 6. Pharm Res. 2017. PMID: 29110283
Coagulation disorders in septic shock.
Thijs LG, de Boer JP, de Groot MC, Hack CE. Thijs LG, et al. Among authors: de boer jp. Intensive Care Med. 1993;19 Suppl 1:S8-15. doi: 10.1007/BF01738944. Intensive Care Med. 1993. PMID: 8227738 Review.
115 results